Eli Lilly 2015 Annual Report Download - page 148

Download and view the complete annual report

Please find page 148 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 186

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186

P32
Shareholder Value Awards
SVAs may be earned based on Lilly's share price performance over a three-year period. SVAs have a three-
year performance period and any shares paid out are subject to a one-year holding requirement. No
dividends are accrued during the performance period. SVAs pay out above target if Lilly stock outperforms an
expected compounded annual rate of return and below target if company stock underperforms that rate of
return. The expected rate of return includes dividends and is based on the total three-year shareholder return
("TSR") that a reasonable investor would consider appropriate for investing in a basket of large-cap U.S.
companies, as determined by the Compensation Committee. The target share price is based on this expected
rate of return less the company’s dividend yield, applied to the starting share price. Executive officers receive
no payout if TSR for the three-year period is zero or negative.
Possible payouts range from 0 to 140 percent of the target amount, depending on stock performance over the
period.
Pay for Performance
The mix of compensation for the CEO and other NEOs reflects our desire to link executive compensation with
company performance. As reflected in the charts below, a substantial portion of the target pay for all NEOs is
performance-based. Both the annual bonus and equity payouts are contingent upon company performance,
with the bonus factoring in performance over a one-year period, and equity compensation factoring in
performance over a longer term (as described above under "Components of Our Compensation - 3. Equity
Incentives").
2015 Target Total Compensation
Performance Review Process
In setting potential EO compensation for 2015, the Compensation Committee considered both individual and
company performance during 2014.
2014 Individual EO Performance
A summary of the committee's review of the individual EOs is provided below: